The human histaminergic system in neuropsychiatric disorders

Trends in Neurosciences

Volumn 38, Issue 3, 2015, Pages 167-177

  Shan, Ling ^a,b,c,d   Bao, Ai Min ^a   Swaab, Dick F ^b  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b NETHERLANDS INSTITUTE FOR NEUROSCIENCE   (Netherlands)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d Neurobiology Research (151A3)   (United States)

Author keywords

Alzheimer's disease; Histamine; Huntington's disease; Narcolepsy; Parkinson's disease; Tourette's syndrome

Indexed keywords

HISTAMINE; HISTAMINE H3 RECEPTOR AGONIST; HISTAMINE H3 RECEPTOR ANTAGONIST;

ALZHEIMER DISEASE; ATTENTION; BRAIN REGION; CIRCADIAN RHYTHM; COGNITION; DEPRESSION; ENERGY BALANCE; GILLES DE LA TOURETTE SYNDROME; HISTAMINE METABOLISM; HISTAMINERGIC NEURON; HISTAMINERGIC SYSTEM; HOMEOSTASIS; HUMAN; HUNTINGTON CHOREA; HYPOTHALAMIC TUBEROMAMILLARY NUCLEUS; HYPOTHALAMUS NUCLEUS; NARCOLEPSY; NERVE CELL; NERVE PROJECTION; NERVOUS SYSTEM; NEUROPSYCHIATRY; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW; SENSORIMOTOR FUNCTION; SLEEP WAKING CYCLE; ANIMAL; BRAIN; MENTAL DISEASE; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY;

ANIMALS; BRAIN; HISTAMINE; HUMANS; MENTAL DISORDERS;

EID: 84924578659     PISSN: 01662236     EISSN: 1878108X     Source Type: Journal    
DOI: 10.1016/j.tins.2014.12.008     Document Type: Review

References (113)

1. Haas H.L., et al. Histamine in the nervous system. Physiol. Rev. 2008, 88:1183-1241.
2. Panula P., et al. The histaminergic network in the brain: basic organization and role in disease. Nat. Rev. Neurosci. 2013, 14:472-487.
3. Panula P., et al. Developmental roles of brain histamine. Trends Neurosci. 2014, 37:159-168.
4. Ercan-Sencicek A.G., et al. L-histidine decarboxylase and Tourette's syndrome. N. Engl. J. Med. 2010, 362:1901-1908.
5. Castellan Baldan L., et al. Histidine decarboxylase deficiency causes tourette syndrome: parallel findings in humans and mice. Neuron 2014, 81:77-90.
6. John J., et al. Greatly increased numbers of histamine cells in human narcolepsy with cataplexy. Ann. Neurol. 2013, 74:786-793.
7. Valko P.O., et al. Increase of histaminergic tuberomammillary neurons in narcolepsy. Ann. Neurol. 2013, 74:794-804.
8. Passani M.B., et al. Histamine receptors in the CNS as targets for therapeutic intervention. Trends Pharmacol. Sci. 2011, 32:242-249.
9. Brioni J.D., et al. Discovery of histamine H3 antagonists for the treatment of cognitive disorders and Alzheimer's disease. J. Pharmacol. Exp. Ther. 2011, 336:38-46.
10. Shan L., et al. Alterations in the histaminergic system in Alzheimer's disease: a postmortem study. Neurobiol. Aging 2012, 33:2585-2598.
11. Airaksinen M.S., et al. Histamine neurons in human hypothalamus: anatomy in normal and Alzheimer diseased brains. Neuroscience 1991, 44:465-481.
12. Anichtchik O.V., et al. An altered histaminergic innervation of the substantia nigra in Parkinson's disease. Exp. Neurol. 2000, 163:20-30.
13. Panula P., et al. A histamine-containing neuronal system in human brain. Neuroscience 1990, 34:127-132.
14. Jin C.Y., et al. The histaminergic system in human thalamus: correlation of innervation to receptor expression. Eur. J. Neurosci. 2002, 15:1125-1138.
15. Krolewski D.M., et al. Expression patterns of corticotropin-releasing factor, arginine vasopressin, histidine decarboxylase, melanin-concentrating hormone, and orexin genes in the human hypothalamus. J. Comp. Neurol. 2010, 518:4591-4611.
16. Watanabe T., et al. L-histidine decarboxylase as a probe in studies on histamine. Chem. Rec. 2002, 2:369-376.
17. Trottier S., et al. Co-localization of histamine with GABA but not with galanin in the human tuberomamillary nucleus. Brain Res. 2002, 939:52-64.
18. Saper C.B., et al. Hypothalamic pathology in Alzheimer's disease. Neurosci. Lett. 1987, 74:364-370.
19. Nakamura S., et al. The histochemical demonstration of monoamine oxidase-containing neurons in the human hypothalamus. Neuroscience 1991, 44:457-463.
20. Hurd Y.L., et al. Human cocaine- and amphetamine-regulated transcript (CART) mRNA is highly expressed in limbic- and sensory-related brain regions. J. Comp. Neurol. 2000, 425:583-598.
21. Garcia-Falgueras A., et al. Galanin neurons in the intermediate nucleus (InM) of the human hypothalamus in relation to sex, age, and gender identity. J. Comp. Neurol. 2011, 519:3061-3084.
22. Takahashi K., et al. Neuronal activity of histaminergic tuberomammillary neurons during wake-sleep states in the mouse. J. Neurosci. 2006, 26:10292-10298.
23. Strecker R.E., et al. Extracellular histamine levels in the feline preoptic/anterior hypothalamic area during natural sleep-wakefulness and prolonged wakefulness: an in vivo microdialysis study. Neuroscience 2002, 113:663-670.
24. Prell G.D., et al. Diurnal fluctuation in levels of histamine metabolites in cerebrospinal fluid of rhesus monkey. Agents Actions 1989, 26:279-286.
25. Liu C.Q., et al. A quantitative in situ hybridization protocol for formalin-fixed paraffin-embedded archival post-mortem human brain tissue. Methods 2010, 52:359-366.
26. Shan L., et al. Diurnal fluctuation in histidine decarboxylase expression, the rate limiting enzyme for histamine production, and its disorder in neurodegenerative diseases. Sleep 2012, 35:713-715.
27. Zeitzer J.M., et al. Time-course of cerebrospinal fluid histamine in the wake-consolidated squirrel monkey. J. Sleep Res. 2012, 21:189-194.
28. Hofman M.A., et al. Diurnal and seasonal rhythms of neuronal activity in the suprachiasmatic nucleus of humans. J. Biol. Rhythms 1993, 8:283-295.
29. Li J.Z., et al. Circadian patterns of gene expression in the human brain and disruption in major depressive disorder. Proc. Natl. Acad. Sci. U.S.A. 2013, 110:9950-9955.
30. Sulzer D. Multiple hit hypotheses for dopamine neuron loss in Parkinson's disease. Trends Neurosci. 2007, 30:244-250.
31. Liu C.Q., et al. Apomorphine-induced turning behavior in 6-hydroxydopamine lesioned rats is increased by histidine and decreased by histidine decarboxylase, histamine H1 and H2 receptor antagonists, and an H3 receptor agonist. Pharmacol. Biochem. Behav. 2008, 90:325-330.
32. Liu C.Q., et al. Involvement of brain endogenous histamine in the degeneration of dopaminergic neurons in 6-hydroxydopamine-lesioned rats. Neuropharmacology 2007, 53:832-841.
33. Rinne J.O., et al. Increased brain histamine levels in Parkinson's disease but not in multiple system atrophy. J. Neurochem. 2002, 81:954-960.
34. Shan L., et al. Neuronal histamine production remains unaltered in Parkinson's disease despite the accumulation of Lewy bodies and Lewy neurites in the tuberomamillary nucleus. Neurobiol. Aging 2012, 33:1343-1344.
35. Braak H., et al. Pattern of brain destruction in Parkinson's and Alzheimer's diseases. J. Neural. Transm. 1996, 103:455-490.
36. Nakamura S., et al. Large neurons in the tuberomammillary nucleus in patients with Parkinson's disease and multiple system atrophy. Neurology 1996, 46:1693-1696.
37. Garbarg M., et al. Brain histidine decarboxylase activity in Parkinson's disease. Lancet 1983, 1:74-75.
38. Prell G.D., et al. Levels of pros-methylimidazoleacetic acid: correlation with severity of Parkinson's disease in CSF of patients and with the depletion of striatal dopamine and its metabolites in MPTP-treated mice. J. Neural. Transm. Park Dis. Dement. Sect. 1991, 3:109-125.
39. Anichtchik O.V., et al. Distribution and modulation of histamine H(3) receptors in basal ganglia and frontal cortex of healthy controls and patients with Parkinson's disease. Neurobiol. Dis. 2001, 8:707-716.
40. Shan L., et al. Alterations in the histaminergic system in the substantia nigra and striatum of Parkinson's patients: a postmortem study. Neurobiol. Aging 2012, 33:1488. e1481-1413.
41. Vizuete M.L., et al. Histamine infusion induces a selective dopaminergic neuronal death along with an inflammatory reaction in rat substantia nigra. J. Neurochem. 2000, 75:540-552.
42. Prell G.D., et al. Elevated levels of histamine metabolites in cerebrospinal fluid of aging, healthy humans. Comp. Gerontol. A 1988, 2:114-119.
43. Cacabelos R., et al. Brain histamine in Alzheimer's disease. Methods Find. Exp. Clin. Pharmacol. 1989, 11:353-360.
44. Fernandez-Novoa L., et al. Histamine function in brain disorders. Behav. Brain Res. 2001, 124:213-233.
45. Mazurkiewicz-Kwilecki I.M., et al. Changes in the regional brain histamine and histidine levels in postmortem brains of Alzheimer patients. Can. J. Physiol. Pharmacol. 1989, 67:75-78.
46. Panula P., et al. Neuronal histamine deficit in Alzheimer's disease. Neuroscience 1998, 82:993-997.
47. Nakamura S., et al. Loss of large neurons and occurrence of neurofibrillary tangles in the tuberomammillary nucleus of patients with Alzheimer's disease. Neurosci. Lett. 1993, 151:196-199.
48. Motawaj M., et al. CSF levels of the histamine metabolite tele-methylhistamine are only slightly decreased in Alzheimer's disease. J. Alzheimers Dis. 2010, 22:861-871.
49. Sabbagh J.J., et al. Animal systems in the development of treatments for Alzheimer's disease: challenges, methods, and implications. Neurobiol. Aging 2013, 34:169-183.
50. Medhurst A.D., et al. Characterization of histamine H3 receptors in Alzheimer's Disease brain and amyloid over-expressing TASTPM mice. Br. J. Pharmacol. 2009, 157:130-138.
51. Medhurst A.D., et al. GSK189254, a novel H3 receptor antagonist that binds to histamine H3 receptors in Alzheimer's disease brain and improves cognitive performance in preclinical models. J. Pharmacol. Exp. Ther. 2007, 321:1032-1045.
52. Bardgett M.E., et al. Ciproxifan, an H3 receptor antagonist, alleviates hyperactivity and cognitive deficits in the APP Tg2576 mouse model of Alzheimer's disease. Neurobiol. Learn. Mem. 2011, 95:64-72.
53. Bitner R.S., et al. In-vivo histamine H3 receptor antagonism activates cellular signaling suggestive of symptomatic and disease modifying efficacy in Alzheimer's disease. Neuropharmacology 2011, 60:460-466.
54. Egan M., et al. Pilot randomized controlled study of a histamine receptor inverse agonist in the symptomatic treatment of AD. Curr. Alzheimer Res. 2012, 9:481-490.
55. Haig G.M., et al. A randomized study of H3 antagonist ABT-288 in mild-to-moderate Alzheimer's dementia. J. Alzheimers Dis. 2014, 42:959-971.
56. Grove R.A., et al. A randomized, double-blind, placebo-controlled, 16-week study of the H3 receptor antagonist, GSK239512 as a monotherapy in subjects with mild-to-moderate Alzheimer's disease. Curr. Alzheimer Res. 2014, 11:47-58.
57. Aziz A., et al. Hypocretin and melanin-concentrating hormone in patients with Huntington disease. Brain Pathol. 2008, 18:474-483.
58. Martinez-Mir M.I., et al. Loss of striatal histamine H2 receptors in Huntington's chorea but not in Parkinson's disease: comparison with animal models. Synapse 1993, 15:209-220.
59. Goodchild R.E., et al. Distribution of histamine H3-receptor binding in the normal human basal ganglia: comparison with Huntington's and Parkinson's disease cases. Eur. J. Neurosci. 1999, 11:449-456.
60. Whitehouse P.J., et al. Neurotransmitter receptor alterations in Huntington's disease: autoradiographic and homogenate studies with special reference to benzodiazepine receptor complexes. Ann. Neurol. 1985, 18:202-210.
61. van Wamelen D.J., et al. Functional increase of brain histaminergic signaling in Huntington's disease. Brain Pathol. 2011, 21:419-427.
62. Prell G.D., et al. Histamine metabolites and pros-methylimidazoleacetic acid in human cerebrospinal fluid. Agents Actions 1991, 33(Suppl.):343-363.
63. Petersen A., et al. Orexin loss in Huntington's disease. Hum. Mol. Genet. 2005, 14:39-47.
64. Eriksson K.S., et al. Orexin/hypocretin excites the histaminergic neurons of the tuberomammillary nucleus. J. Neurosci. 2001, 21:9273-9279.
65. Williams R.H., et al. Paradoxical function of orexin/hypocretin circuits in a mouse model of Huntington's disease. Neurobiol. Dis. 2011, 42:438-445.
66. Wang S.S., et al. Gene expression analysis in the human hypothalamus in depression by laser microdissection and real-time PCR: the presence of multiple receptor imbalances. Mol. Psychiatry 2008, 13:786-799. 741.
67. Bao A.M., et al. Corticotropin-releasing hormone and arginine vasopressin in depression focus on the human postmortem hypothalamus. Vitam Horm 2010, 82:339-365.
68. Knigge U., et al. Stress-induced release of anterior pituitary hormones: effect of H3 receptor-mediated inhibition of histaminergic activity or posterior hypothalamic lesion. Neuroendocrinology 1999, 69:44-53.
69. Ito C. The role of brain histamine in acute and chronic stresses. Biomed. Pharmacother. 2000, 54:263-267.
70. Mazurkiewicz-Kwilecki I.M., et al. Brain histamine response to stress in 12 month old rats. Life Sci. 1986, 38:2339-2345.
71. Mazurkiewicz-Kwilecki I.M. Single and repeated air blast stress and brain histamine. Pharmacol. Biochem. Behav. 1980, 12:35-39.
72. Taylor K.M., et al. Brain histamine: rapid apparent turnover altered by restraint and cold stress. Science 1971, 172:1037-1039.
73. Ito C., et al. Effects of the acute and chronic restraint stresses on the central histaminergic neuron system of Fischer rat. Neurosci. Lett. 1999, 262:143-145.
74. Noguchi S., et al. Possible contributory role of the central histaminergic system in the forced swimming model. Arzneimittelforschung 1992, 42:611-613.
75. Kano M., et al. Decreased histamine H1 receptor binding in the brain of depressed patients. Eur. J. Neurosci. 2004, 20:803-810.
76. Shan L., et al. Unaltered histaminergic system in depression: a postmortem study. J. Affect. Disord. 2013, 146:220-223.
77. John J., et al. Cataplexy-active neurons in the hypothalamus: implications for the role of histamine in sleep and waking behavior. Neuron 2004, 42:619-634.
78. Thannickal T.C., et al. Reduced number of hypocretin neurons in human narcolepsy. Neuron 2000, 27:469-474.
79. Peyron C., et al. A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains. Nat. Med. 2000, 6:991-997.
80. Chemelli R.M., et al. Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation. Cell 1999, 98:437-451.
81. Hara J., et al. Genetic ablation of orexin neurons in mice results in narcolepsy, hypophagia, and obesity. Neuron 2001, 30:345-354.
82. Tabuchi S., et al. Conditional ablation of orexin/hypocretin neurons: a new mouse model for the study of narcolepsy and orexin system function. J. Neurosci. 2014, 34:6495-6509.
83. Torrealba F., et al. Colocalization of orexin a and glutamate immunoreactivity in axon terminals in the tuberomammillary nucleus in rats. Neuroscience 2003, 119:1033-1044.
84. Schone C., et al. Optogenetic probing of fast glutamatergic transmission from hypocretin/orexin to histamine neurons in situ. J. Neurosci. 2012, 32:12437-12443.
85. Huang Z.L., et al. Arousal effect of orexin A depends on activation of the histaminergic system. Proc. Natl. Acad. Sci. U.S.A. 2001, 98:9965-9970.
86. Nishino S., et al. Decreased CSF histamine in narcolepsy with and without low CSF hypocretin-1 in comparison to healthy controls. Sleep 2009, 32:175-180.
87. Dauvilliers Y., et al. Normal cerebrospinal fluid histamine and tele-methylhistamine levels in hypersomnia conditions. Sleep 2012, 35:1359-1366.
88. Inocente C., et al. Pitolisant, an inverse agonist of the histamine H3 receptor: an alternative stimulant for narcolepsy-cataplexy in teenagers with refractory sleepiness. Clin. Neuropharmacol. 2012, 35:55-60.
89. Lin J.S., et al. An inverse agonist of the histamine H(3) receptor improves wakefulness in narcolepsy: studies in orexin-/- mice and patients. Neurobiol. Dis. 2008, 30:74-83.
90. Dauvilliers Y., et al. Pitolisant versus placebo or modafinil in patients with narcolepsy: a double-blind, randomised trial. Lancet Neurol. 2013, 12:1068-1075.
91. Ohtsu H., et al. Mice lacking histidine decarboxylase exhibit abnormal mast cells. FEBS Lett. 2001, 502:53-56.
92. Schneider E.H., et al. Modulation of behavior by the histaminergic system: Lessons from HR-and HR-deficient mice. Neurosci. Biobehav. Rev. 2014, 42C:252-266.
93. Scammell T.E., et al. A consensus definition of cataplexy in mouse models of narcolepsy. Sleep 2009, 32:111-116.
94. Fernandez-Guasti A., et al. Sex differences in the distribution of androgen receptors in the human hypothalamus. J. Comp. Neurol. 2000, 425:422-435.
95. Mochizuki H., et al. The effects of a sedative antihistamine, d-chlorpheniramine, on visuomotor spatial discrimination and regional brain activity as measured by positron emission tomography (PET). Hum. Psychopharmacol. 2002, 17:413-418.
96. Masaki T., et al. The hypothalamic H1 receptor: a novel therapeutic target for disrupting diurnal feeding rhythm and obesity. Trends Pharmacol. Sci. 2006, 27:279-284.
97. Inoue I., et al. Impaired locomotor activity and exploratory behavior in mice lacking histamine H1 receptors. Proc. Natl. Acad. Sci. U.S.A. 1996, 93:13316-13320.
98. Dai H., et al. Selective cognitive dysfunction in mice lacking histamine H1 and H2 receptors. Neurosci. Res. 2007, 57:306-313.
99. Martinez-Mir M.I., et al. Three histamine receptors (H1, H2 and H3) visualized in the brain of human and non-human primates. Brain Res. 1990, 526:322-327.
100. Fitzsimons C.P., et al. Histamine deficiency induces tissue-specific down-regulation of histamine H2 receptor expression in histidine decarboxylase knockout mice. FEBS Lett. 2001, 508:245-248.
101. Jin C.Y., et al. The laminar histamine receptor system in human prefrontal cortex suggests multiple levels of histaminergic regulation. Neuroscience 2005, 132:137-149.
102. Chazot P.L., et al. Immunological identification of the mammalian H3 histamine receptor in the mouse brain. Neuroreport 2001, 12:259-262.
103. Pillot C., et al. A detailed mapping of the histamine H(3) receptor and its gene transcripts in rat brain. Neuroscience 2002, 114:173-193.
104. Sander K., et al. Histamine H3 receptor antagonists go to clinics. Biol. Pharm. Bull. 2008, 31:2163-2181.
105. Blandina P., et al. Histamine H3 receptor inhibition of K(+)-evoked release of acetylcholine from rat cortex in vivo. Inflamm. Res. 1996, 45(Suppl. 1):S54-S55.
106. Schlicker E., et al. H3 receptor-mediated inhibition of noradrenaline release: an investigation into the involvement of Ca2+ and K+ ions, G protein and adenylate cyclase. Naunyn Schmiedebergs Arch. Pharmacol. 1994, 350:34-41.
107. Egan M.F., et al. Randomized crossover study of the histamine H3 inverse agonist MK-0249 for the treatment of cognitive impairment in patients with schizophrenia. Schizophr. Res. 2013, 146:224-230.
108. Coge F., et al. Structure and expression of the human histamine H4-receptor gene. Biochem. Biophys. Res. Commun. 2001, 284:301-309.
109. Connelly W.M., et al. The histamine H4 receptor is functionally expressed on neurons in the mammalian CNS. Br. J. Pharmacol. 2009, 157:55-63.
110. Beermann S., et al. Commercially available antibodies against human and murine histamine H(4)-receptor lack specificity. Naunyn Schmiedebergs Arch. Pharmacol. 2012, 385:125-135.
111. Rafalowska U., et al. Is neurotransmitter histamine predominantly inactivated in astrocytes?. Neurosci. Lett. 1987, 80:106-110.
112. Huszti Z., et al. Glial cells participate in histamine inactivation in vivo. Naunyn Schmiedebergs Arch. Pharmacol. 1998, 357:49-53.
113. Kanbayashi T., et al. CSF histamine contents in narcolepsy, idiopathic hypersomnia and obstructive sleep apnea syndrome. Sleep 2009, 32:181-187.